200 related articles for article (PubMed ID: 33199755)
1. Metabolic interaction between amino acid deprivation and cisplatin synergistically reduces phosphoribosyl-pyrophosphate and augments cisplatin cytotoxicity.
Wahwah N; Dhar D; Chen H; Zhuang S; Chan A; Casteel DE; Kalyanaraman H; Pilz RB; Boss GR
Sci Rep; 2020 Nov; 10(1):19907. PubMed ID: 33199755
[TBL] [Abstract][Full Text] [Related]
2. Role of cellular ribose-5-phosphate content in the regulation of 5-phosphoribosyl-1-pyrophosphate and de novo purine synthesis in a human hepatoma cell line.
Boer P; Sperling O
Metabolism; 1995 Nov; 44(11):1469-74. PubMed ID: 7476336
[TBL] [Abstract][Full Text] [Related]
3. Early mitogenic stimulation of metabolic flux through phosphoribosyl pyrophosphate into nucleotides in Swiss 3T3 cells and requirement of external magnesium for the response.
Tatibana M; Ishijima S; Kita K; Ishizuka T; Suzuki N
Adv Enzyme Regul; 1989; 28():147-66. PubMed ID: 2483026
[TBL] [Abstract][Full Text] [Related]
4. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts.
Zoref E; De Vries A; Sperling O
J Clin Invest; 1975 Nov; 56(5):1093-9. PubMed ID: 171280
[TBL] [Abstract][Full Text] [Related]
5. Synergy of Raddeanin A and cisplatin induced therapeutic effect enhancement in human hepatocellular carcinoma.
Li JN; Yu Y; Zhang YF; Li ZM; Cai GZ; Gong JY
Biochem Biophys Res Commun; 2017 Apr; 485(2):335-341. PubMed ID: 28219642
[TBL] [Abstract][Full Text] [Related]
6. Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy.
Pal Singh M; Pal Khaket T; Bajpai VK; Alfarraj S; Kim SG; Chen L; Huh YS; Han YK; Kang SC
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158052
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
8. Cyclic AMP decreases the availability of 5-phosphoribosyl-1-pyrophosphate and decelerates de novo purine synthesis in rat hepatocytes.
Boer P; Giler S; Sperling O
Life Sci; 1998; 62(23):2133-9. PubMed ID: 9627092
[TBL] [Abstract][Full Text] [Related]
9. On-demand utilization of phosphoribosyl pyrophosphate by downstream anabolic pathways.
Pinson B; Moenner M; Saint-Marc C; Granger-Farbos A; Daignan-Fornier B
J Biol Chem; 2023 Aug; 299(8):105011. PubMed ID: 37414150
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.
Lau CK; Yang ZF; Lam SP; Lam CT; Ngai P; Tam KH; Poon RT; Fan ST
Cancer Biol Ther; 2007 Dec; 6(12):1900-7. PubMed ID: 18059167
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activity.
Fry DW; Boritzki TJ; Jackson RC; Cook PD; Leopold WR
Mol Pharmacol; 1993 Aug; 44(2):479-85. PubMed ID: 7689145
[TBL] [Abstract][Full Text] [Related]
12. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphoribosylpyrophosphate synthetase by 4-methoxy-(MRPP) and 4-amino-8-(D-ribofuranosylamino) pyrimido[5,4-d]pyrimidine (ARPP).
Nord LD; Willis RC; Breen TS; Avery TL; Finch RA; Sanghvi YS; Revankar GR; Robins RK
Biochem Pharmacol; 1989 Oct; 38(20):3543-9. PubMed ID: 2479382
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle regulation of purine synthesis by phosphoribosyl pyrophosphate and inorganic phosphate.
Fridman A; Saha A; Chan A; Casteel DE; Pilz RB; Boss GR
Biochem J; 2013 Aug; 454(1):91-9. PubMed ID: 23734909
[TBL] [Abstract][Full Text] [Related]
15. Phosphoribosylpyrophosphate synthesis in cultured human cells.
Benke PJ; Dittmar D
Science; 1977 Dec; 198(4322):1171-3. PubMed ID: 201027
[TBL] [Abstract][Full Text] [Related]
16. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
[TBL] [Abstract][Full Text] [Related]
17. Effects of uridine diphosphoglucose (UDPG) infusion on 5-phosphoribosyl pyrophosphate (PRPP) levels of mouse tissues.
Yip LC; Xu YL; Balis ME
Biochem Pharmacol; 1987 Mar; 36(5):633-7. PubMed ID: 2435292
[TBL] [Abstract][Full Text] [Related]
18. Contribution of Model Organisms to Investigating the Far-Reaching Consequences of PRPP Metabolism on Human Health and Well-Being.
Ugbogu EA; Schweizer LM; Schweizer M
Cells; 2022 Jun; 11(12):. PubMed ID: 35741038
[TBL] [Abstract][Full Text] [Related]
19. Phosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance.
Hove-Jensen B; Andersen KR; Kilstrup M; Martinussen J; Switzer RL; Willemoës M
Microbiol Mol Biol Rev; 2017 Mar; 81(1):. PubMed ID: 28031352
[TBL] [Abstract][Full Text] [Related]
20. [PRPP synthetase superactivity].
Fujimori S
Nihon Rinsho; 1996 Dec; 54(12):3309-14. PubMed ID: 8976111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
